Praxis Precision Medicines (PRAX) Consolidated Net Income (2019 - 2026)

Praxis Precision Medicines' Consolidated Net Income history runs 8 years deep, the most recent figure standing at -$562.1 million for Q1 2026.

• In Q1 2026, Consolidated Net Income fell 641.16% year-over-year to -$562.1 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 165.03% YoY), while the FY2025 annual figure was -$736.1 million, down 75.91% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$562.1 million, down from -$507.0 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$25.7 million in Q3 2023, with the low at -$562.1 million in Q1 2026.
• The 5-year median for Consolidated Net Income is -$75.8 million (2025), against an average of -$143.2 million.
• The sharpest annual moves came in 2023 and 2026: Consolidated Net Income surged 54.43% in 2023, then tumbled 641.16% in 2026.
• Praxis Precision Medicines' Consolidated Net Income stood at -$184.1 million in 2022, then fell by 13.17% to -$208.3 million in 2023, then sank by 35.5% to -$282.3 million in 2024, then sank by 79.62% to -$507.0 million in 2025, then decreased by 10.87% to -$562.1 million in 2026.
• Business Quant data shows PRAX's Consolidated Net Income at -$562.1 million in Q1 2026, -$507.0 million in Q4 2025, and -$87.0 million in Q3 2025.